(-1.57%) 5 035.69 points
(-1.49%) 37 816 points
(-2.04%) 15 658 points
(-1.39%) $81.48
(-3.69%) $1.955
(-2.56%) $2 297.40
(-3.94%) $26.57
(-1.62%) $945.95
(0.53%) $0.937
(1.18%) $11.11
(0.52%) $0.800
(0.17%) $93.46
-1.41% $ 1.400
@ $3.99
Emitido: 6 feb 2024 @ 09:45
Retorno: -64.91%
Live Chart Being Loaded With Signals
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy...
Stats | |
---|---|
Volumen de hoy | 193 780 |
Volumen promedio | 833 000 |
Capitalización de mercado | 3.43M |
EPS | $0 ( 2023-08-07 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 0 |
ATR14 | $0.0130 (0.93%) |
Volumen Correlación
SciSparc Ltd. Correlación
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
SciSparc Ltd. Correlación - Moneda/Commodity
SciSparc Ltd. Finanzas
Annual | 2023 |
Ingresos: | $2.88M |
Beneficio Bruto: | $2.20M (76.28 %) |
EPS: | $-12.55 |
FY | 2023 |
Ingresos: | $2.88M |
Beneficio Bruto: | $2.20M (76.28 %) |
EPS: | $-12.55 |
FY | 2022 |
Ingresos: | $1.35M |
Beneficio Bruto: | $1.03M (76.10 %) |
EPS: | $-14.73 |
FY | 2021 |
Ingresos: | $0.00 |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-0.160 |
Financial Reports:
No articles found.
SciSparc Ltd.
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico